← AgentSite Network

carricktherapeutics.com

AI-friendly mirror of carricktherapeutics.com for archive, retrieval, and machine reading.

Total Pages
80
Total Words
31,060
Cache Generated
July 26, 2026
Resources
llms.txt— AI crawler index
sitemap.xml— XML sitemap
robots.txt— crawler directives
About this Cache— methodology and usage notes
Identity
primary.md— primary company profilepublic
identity.md— cache identity profilepublic
voice.md— voice and tone guidepublic
manifest.json— manifest metadatapublic
Content Index
▸website80 pages
Homepage
▸investors44 pages
ESG :: Carrick Therapeutics, Inc.
▸news-events17 pages
Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.
Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination :: Carrick Therapeutics, Inc.
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination :: Carrick Therapeutics, Inc.
Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer :: Carrick Therapeutics, Inc.
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.
… 12 more pages
▸sec-filings9 pages
rss
rss
rss
rss
Section 16 Filings :: Carrick Therapeutics, Inc.
… 4 more pages
▸corporate-governance6 pages
Corporate Governance :: Carrick Therapeutics, Inc.
Board of Directors :: Carrick Therapeutics, Inc.
Board Diversity :: Carrick Therapeutics, Inc.
Whistleblower Policy :: Carrick Therapeutics, Inc.
Governance Documents :: Carrick Therapeutics, Inc.
… 1 more pages
… 11 more pages
▸news-media17 pages
Posters & Publications :: Carrick Therapeutics, Inc.
IR Calendar :: Carrick Therapeutics, Inc.
News & Media :: Carrick Therapeutics, Inc.
▸press-releases12 pages
Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination :: Carrick Therapeutics, Inc.
rss
Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination :: Carrick Therapeutics, Inc.
… 7 more pages
▸in-the-news2 pages
rss
In The News :: Carrick Therapeutics, Inc.
view all 17 pages
Email Alerts :: Carrick Therapeutics, Inc.
▸about4 pages
Board of Directors & Observers :: Carrick Therapeutics, Inc.
Management Team :: Carrick Therapeutics, Inc.
Collaborators & Advisors :: Carrick Therapeutics, Inc.
About :: Carrick Therapeutics, Inc.
view all 4 pages
▸science4 pages
Posters & Publications :: Carrick Therapeutics, Inc.
Science :: Carrick Therapeutics, Inc.
CDK7 Biology Schematic :: Carrick Therapeutics, Inc.
CDK1213 Biology Schematic :: Carrick Therapeutics, Inc.
view all 4 pages
Cookie Policy :: Carrick Therapeutics, Inc.
Privacy Policy :: Carrick Therapeutics, Inc.
▸pipeline3 pages
CDK7 Inhibitor :: Carrick Therapeutics, Inc.
CDK12/13 Inhibitor :: Carrick Therapeutics, Inc.
Pipeline :: Carrick Therapeutics, Inc.
view all 3 pages
Partnering :: Carrick Therapeutics, Inc.
Disclaimer :: Carrick Therapeutics, Inc.
Careers :: Carrick Therapeutics, Inc.
Contact :: Carrick Therapeutics, Inc.